PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.
Trace metal homeostasis is critical for cellular function and often disrupted in diseases such as cancer. Spatially resolved techniques enable mapping of metal distributions within complex cellular environments, surpassing the limitations of bulk analyses. Formalin-fixed, paraffin-embedded (FFPE) tissues are widely used in research, yet the impact of FFPE processing on endogenous elemental contents and distributions remains unclear, with conflicting findings across sample types. This study evaluates the suitability of FFPE human breast carcinoma tissue sections for multielemental bioimaging by direct comparison with paired fresh frozen (FF) tissues and assesses potential sources of contamination or elemental losses during processing. Three FF human breast carcinoma specimens were bisected and processed as either FF or FFPE. Serial sections underwent analyses by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), alongside hematoxylin and eosin (H&E)-staining, to compare elemental profiles in whole sections and morphologically distinct regions. In parallel, FFPE processing reagents encompassing tissue-marking dyes, formalin, paraffin wax, xylene, and ethanol were analyzed via solution ICP-MS to contextualize the in situ findings. The multielemental imaging results revealed that Zn, Mn, and Fe were largely preserved in FFPE sections, supporting the continued use of such tissues for in situ metal analyses. Addition of Cu was observed for all FFPE samples, most likely caused by exposure to blue tissue-marking dye. Formalin induced variable elemental leaching, most notably affecting Mg. Paraffin wax, ethanol, and xylene contained minimal trace metal levels both before and after contact with tissues.